GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » Revenue

Apontis Pharma AG (XTER:APPH) Revenue : €36.96 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG Revenue?

Apontis Pharma AG's revenue for the six months ended in Dec. 2023 was €17.91 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €36.96 Mil. Apontis Pharma AG's Revenue per Share for the six months ended in Dec. 2023 was €2.11. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €4.35.

Warning Sign:

Apontis Pharma AG revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Apontis Pharma AG was -33.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Apontis Pharma AG's highest 3-Year average Revenue per Share Growth Rate was 11.70% per year. The lowest was -2.00% per year. And the median was 4.85% per year.


Apontis Pharma AG Revenue Historical Data

The historical data trend for Apontis Pharma AG's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apontis Pharma AG Revenue Chart

Apontis Pharma AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 40.04 39.24 51.18 55.73 36.96

Apontis Pharma AG Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only 27.17 28.11 27.62 19.06 17.91

Competitive Comparison of Apontis Pharma AG's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apontis Pharma AG's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Revenue distribution charts can be found below:

* The bar in red indicates where Apontis Pharma AG's Revenue falls into.



Apontis Pharma AG Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €36.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apontis Pharma AG  (XTER:APPH) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Apontis Pharma AG Revenue Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Apontis Pharma AG (XTER:APPH) Business Description

Traded in Other Exchanges
N/A
Address
Alfred-Nobel-Strabe 10, Monheim, BY, DEU, 40789
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases.
Executives
Karlheinz Gast Board of Directors
Thomas Milz Board of Directors

Apontis Pharma AG (XTER:APPH) Headlines

No Headlines